Compare Bristol-Myers Squibb Co (BMY) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Cisco Systems Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.29 (market cap $116.30B), while Cisco Systems Inc trades at $114.5 (market cap $461.50B). The key difference: Cisco Systems Inc is far larger — about 4× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | CSCO | |
|---|---|---|
Market Cap | $116.30B | $461.50B |
Sector | Health | Technology |
52-Week High | $62.37 | $130.00 |
52-Week Low | $42.60 | $66.20 |
Enterprise Value | $152.24B | $476.17B |
Dividend Yield | 4.42% | 1.43% |
Volume | — | 22,887,319 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Cisco Systems (CSCO) trades at $119.25, down 1.7% over 24 hours, with a bullish technical signal from moving averages and recent AI-driven news boosting sentiment. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.06 exceeding the $1.03 estimate. Financials show solid profitability with a 64.33% gross margin and $10.18B net income for 2025, though valuation ratios like P/E of 39.03 appear elevated. Analyst consensus is bullish with a $130.38 price target, supported by 38 buy ratings.
Outlook remains positive due to AI cybersecurity demand and partnerships, but risks include high debt levels and competitive pressures. The stock offers growth potential from tech infrastructure trends, yet investors should monitor execution on AI initiatives and macroeconomic headwinds that could impact networking spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
